Document is current
Any future updates will be listed below
-
Authors
Petljak, Mia https://orcid.org/0000-0001-8361-5390
Dananberg, Alexandra
Chu, Kevan
Bergstrom, Erik N.
Striepen, Josefine
von Morgen, Patrick https://orcid.org/0000-0002-0614-6292
Chen, Yanyang https://orcid.org/0000-0003-4665-9671
Shah, Hina
Sale, Julian E. https://orcid.org/0000-0002-5031-3780
Alexandrov, Ludmil B.
Stratton, Michael R. https://orcid.org/0000-0001-6035-153X
Maciejowski, John https://orcid.org/0000-0001-8134-9308
- License Information
-
More Information
Article History
Received: 13 February 2021
Accepted: 13 June 2022
First Online: 20 July 2022
Competing interests
: M.P. is a shareholder in Vertex Pharmaceuticals and a compensated consultant for the GLG Network. J.M. has received consulting fees from Ono Pharmaceutical Co. His spouse is an employee of and has equity in Bristol Myers Squibb. J.M., M.P. and M.R.S. are inventors of the patent application ‘Tracking APOBEC mutational signatures in tumor cells’ (PCT/US2022/013328) by Broad, MSKCC, and Sanger (patent pending). L.B.A. is a compensated consultant and has equity interest in io9. His spouse is an employee of Biotheranostics. L.B.A. is also listed as an inventor on US Patent 10,776,718 for source identification by non-negative matrix factorization. E.N.B. and L.B.A. declare provisional patent applications for ‘Clustered mutations for the treatment of cancer’ (US provisional application serial number 63/289,601) and ‘Artificial intelligence architecture for predicting cancer biomarker’ (serial number 63/269,033). The other authors declare no competing interests.
